These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38825630)

  • 1. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
    Cen C; Fan Z; Ding X; Tu X; Liu Y
    Sci Rep; 2024 Jun; 14(1):12645. PubMed ID: 38825630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
    Li H; Zhang Y; Luo H; Lin R
    Front Endocrinol (Lausanne); 2022; 13():977625. PubMed ID: 36407325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
    Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
    J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
    Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
    Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
    Pan Z; Derbala M; AlNaamani K; Ghazinian H; Fan JG; Eslam M
    Ann Hepatol; 2024; 29(5):101512. PubMed ID: 38710473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
    Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
    Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
    Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease: A cross-sectional study.
    Badawi R; Fahmy Abou Taira NS; Hasby SE; Elkhalawany W; Elrefaey W; Ahmed Khalf N; Ibrahim Okda H
    Saudi Med J; 2024 Oct; 45(10):1034-1040. PubMed ID: 39379109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
    Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
    Wei S; Song J; Xie Y; Huang J; Yang J
    JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
    Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
    Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
    Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
    BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States.
    Dao AD; Nguyen VH; Ito T; Cheung R; Nguyen MH
    Hepatol Int; 2023 Feb; 17(1):225-236. PubMed ID: 36309601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
    Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
    Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.